A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO/PACLITAXEL-CONTROLLED STUDY OF BATIRAXCEPT IN COMBINATION WITH WEEKLY PACLITAXEL IN PATIENTS WITH PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (GOG-3059/ENGOT OV-66)

被引：1

作者：

Fuh, Katherine ^{[1
]}

Moore, Kathleen ^{[2
]}

Baert, Thais ^{[3
]}

Herzog, Thomas ^{[4
]}

Cibula, David ^{[5
,6
]}

Liu, Joyce ^{[7
]}

Eberst, Laurianne ^{[8
]}

Lewin, Sharon ^{[9
]}

Secord, Angeles Alvarez ^{[10
]}

Sehouli, Jalid ^{[11
]}

Myers, Tashanna ^{[12
]}

Bamias, Aristotelis ^{[13
]}

Rimel, B. J. ^{[14
]}

Colombo, Nicoletta ^{[15
]}

Franke, Amy ^{[16
]}

Shoop, Dipti ^{[17
]}

De Giorgi, Ugo ^{[18
]}

Pikiel, Joanna ^{[19
]}

Bowen, Rebecca ^{[20
]}

Gonzalez-Martin, Antonio ^{[21
]}

机构：

[1] Univ Calif San Francisco, Ob Gyn, San Francisco, CA 94143 USA

[2] Univ Oklahoma, Hlth Sci Ctr, Dept Gynecol Oncol, Stephenson Canc Ctr,Div Obstet & Gynecol, Oklahoma City, OK USA

[3] UZ Leuven, Ob Gyn, Leuven, Belgium

[4] Univ Cincinnati, Ctr Canc, Obstet & Gynecol, Cincinnati, OH USA

[5] Charles Univ Prague, Fac Med 1, Prague, Czech Republic

[6] Gen Univ Hosp, Dept Obstet & Gynecol, Prague, Czech Republic

[7] Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA

[8] Inst Cancerol Strasbourg Europe, Oncol, Lyon, France

[9] HolyName Patricia Lynch Canc Ctr, Gynecol Oncol, Teaneck, NJ USA

[10] Duke, Ob Gyn, Durham, NC USA

[11] Charite Univ Med Berlin, Dept Gynecol, Ctr Oncol Surg, Campus Virchow Klinikum, Berlin, Germany

[12] Baystate Med Ctr, Div Gynecol Oncol, Obstet & Gynecol, Springfield, MA 01199 USA

[13] Attikon Gen Univ Hosp Athens, Oncol, Athens, Greece

[14] Cedars Sinai Med Ctr, Gynecol Oncol, Los Angeles, CA 90048 USA

[15] Univ Milano Bicocca, European Inst Oncol IRCCS, Dept Gynecol Oncol, Milan, Italy

[16] Aravive, Oncol, Houston, TX USA

[17] Aravive, Biol, Houston, TX USA

[18] Stituto Romagnolo Studio Tumori IRST Dino Amadori, Urogynecol, Meldola, Italy

[19] Reg Ctr Oncol, Dept Chemotherapy, Gdansk, Poland

[20] Royal United Hosp Bath, Oncol, Bath, Avon, England

[21] Clin Univ Navarra, Med Oncol, Madrid, Spain

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2022年 / 32卷

关键词：

D O I：

10.1136/ijgc-2022-igcs.532

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TP023/#156

引用

页码：A234 / A235

页数：2

共 50 条

[1] AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer
Fuh, Katherine Cynthia
Tsitsishvili, Zaza
Reid, Thomas J.
De Giorgi, Ugo
Hand, Lauren
Bowen, Rebecca
Miller, Devin
Vulsteke, Christof
Sharma, Sudarshan K.
Chudecka-Glaz, Anita M.
Liu, Joyce F.
Eberst, Lauriane
Neff, Robert
Lim, Peter C.
Iglesias, David A.
Jenkins Vogel, Tilley
Myers, Tashanna K. N.
Gonzalez-Martin, Antonio
Gonzalez Martin, Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA5515 - LBA5515
[2] A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66/AVB500-OC-004).
Fuh, Katherine Cynthia
Herzog, Thomas J.
Moore, Kathleen N.
Myers, Tashanna K. N.
Rimel, B. J.
Liu, Joyce F.
Secord, Angeles Alvarez
Hamilton, Erika P.
Reid, Thomas J.
Lewin, Sharyn Nan
Mullen, Mary M.
Mills, Kathryn A.
Anderson, Randy
Rangwala, Reshma A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[3] ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer.
Colombo, Nicoletta
Coleman, Robert L.
Wu, Xiaohua
Kose, Fatih
Wenham, Robert Michael
Sebastianelli, Alexandra
Hasegawa, Kosei
Zsiros, Emese
Rouge, Thibault De la Motte
Bidzinski, Mariusz
McNeish, Iain A.
Sehouli, Jalid
Korach, Jacob
Debruyne, Philip R.
Kim, Jae-Weon
De Melo, Andrea C.
Peng, Xuan
Bogusz, Agata M.
Yamada, Karin Sayuri
Monk, Bradley J.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[4] ENGOT-ov65/KEYNOTE-B96: Phase III, randomized, double-blind study of pembrolizumab vs placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer
Colombo, N.
Coleman, R. L.
Wu, X.
Kose, F.
Wenham, R.
Sebastianelli, A.
Hasegawa, K.
Zsiros, E.
Rouge, T. De La Motte
Bidzinski, M.
McNeish, I.
Sehouli, J.
Korach, J.
Debruyne, P. R.
Kim, J-W.
De Melo, A. C.
Peng, X.
Bogusz, A. M.
Yamada, K.
Monk, B. J.
ANNALS OF ONCOLOGY, 2022, 33 : S400 - S401
[5] Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer
Garcia, AA
O'Meara, A
Bahador, A
Facio, G
Jeffers, S
Kim, DY
Roman, L
GYNECOLOGIC ONCOLOGY, 2004, 93 (02) : 493 - 498
[6] Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
Karlan, Beth Y.
Oza, Amit M.
Richardson, Gary E.
Provencher, Diane M.
Hansen, Vincent L.
Buck, Martin
Chambers, Setsuko K.
Ghatage, Prafull
Pippitt, Charles H., Jr.
Brown, John V., III
Covens, Allan
Nagarkar, Raj V.
Davy, Margaret
Leath, Charles A., III
Hoa Nguyen
Stepan, Daniel E.
Weinreich, David M.
Tassoudji, Marjan
Sun, Yu-Nien
Vergote, Ignace B.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04) : 362 - 371
[7] A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer
Elit, L.
Konner, J. A.
Armstrong, D. K.
Buck, M.
Dean, A.
Finkler, N. J.
Hulstine, A.
Schweizer, C.
Phillips, M.
Weil, S.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[8] PHASE 3 TRIAL OF TUMOR TREATING FIELDS CONCOMITANT WITH WEEKLY PACLITAXEL FOR PLATINUM-RESISTANT OVARIAN CANCER: ENGOT-OV50/GOG-329/INNOVATE-3
Vergote, Ignace B.
Sehouli, Jalid
Fossati, Roldano
Coleman, Robert
Monk, Bradley
Copeland, Larry
O'malley, David
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A113 - A113
[9] PHASE 3 TRIAL OF TUMOR TREATING FIELDS CONCOMITANT WITH WEEKLY PACLITAXEL FOR PLATINUM-RESISTANT OVARIAN CANCER: ENGOT-OV50/GOG-329/INNOVATE-3
Vergote, I.
Salutari, V.
Cibula, D.
Korach, J.
Samartzis, E. P.
Sehouli, J.
Fossati, R.
Martin, A. G.
Tsibulak, I.
Slomovitz, B.
Coleman, R.
Monk, B.
Thaker, P.
O'Malley, D.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A147 - A148
[10] TUMOR TREATING FIELDS (200 KHZ) CONCOMITANT WITH WEEKLY PACLITAXEL FOR PLATINUM-RESISTANT OVARIAN CANCER: PHASE 3 INNOVATE/ENGOT-OV50 STUDY
Vergote, I.
Copeland, L.
Monk, B.
Coleman, R.
Cibula, D.
Sehouli, J.
Samartzis, E. P.
Madry, R.
Gonzalez Martin, A.
Korach, J.
Salutari, V.
Witteveen, P. O.
O'Malley, D.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A151 - A152

← 1 2 3 4 5 →